Partners using AI and machine learning for drug discovery
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at Cambridge University have formed an alliance to use artificial intelligence and machine learning to identify and validate new drug targets in immuno-oncology and respiratory diseases.
Cutting-edge machine learning approaches will be developed, validated and integrated into drug discovery processes to identify novel therapeutic targets, stratify patient populations and predict efficacy of new and existing drugs.
Data generated will enhance the design of key experiments to validate and prioritise targets. Scientists involved in the project will be co-located at LifeArc and Milner Therapeutics to take full advantage of both environments.
Professor Tony Kouzarides (pictured), director of the Milner Therapeutics Institute said: “We are delighted to be working closely with LifeArc in applying artificial intelligence and machine learning approaches to drug discovery.
“There is a lot of interest in these methods for the potential to benefit patients. The drug discovery insight and investment from LifeArc will be important in realising this.”
Dr Justin Bryans, executive director for drug discovery at LifeArc added: “Drug discovery is a long and risky process and the collaboration represents a powerful way to unlock new potential approaches to help patients.
“We are excited about the opportunity to work at the interface of drug discovery and AI and apply the knowledge in this field to help expedite the delivery of new treatments to patients.”
• The Milner Therapeutics Institute and LifeArc are seeking academic and industrial partners to work in all therapeutic areas. For more information on how to collaborate email either info [at] milner.cam.ac.uk or info [at] lifearc.org